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Abstract
The human T cell leukemia virus type 1 (HTLV-1) genome contains a cluster of at least five open reading frames (ORFs) near the 3
terminus within the pX region. The pX ORFs are encoded by mono- or bicistronic mRNAs that are generated by alternative splicing. The
various pX mRNAs result from skipping of the internal exon (2-exon versus 3-exon isofoms) or from the utilization of alternative splice
acceptor sites in the terminal exon. The Rex and Tax proteins, encoded by ORFs X-III and X-IV, have been studied intensively and are
encoded by the most abundant of the alternative 3-exon mRNAs. The protein products of the other pX ORFs have not been detected in
HTLV-1-infected cell lines and the levels of the corresponding mRNAs have not been accurately established. We have used real-time
RT-PCR with splice-site specific primers to accurately measure the levels of individual pX mRNA species in chronically infected T cell
lines. We have asked whether virus regulatory proteins or ectopic expression of cellular factors influence pX mRNA splicing in cells that
were transfected with HTLV-1 provirus clones. In chronically infected cell lines, the pX-tax/rex mRNA was present at 500- to 2500-fold
higher levels than the pX-tax-orfII mRNA and at approximately 1000-fold higher levels than pX-rex-orfI mRNA. Chronically infected cell
lines that contain numerous defective proviruses expressed 2-exon forms of pX mRNAs at significantly higher levels compared to cell lines
that contain a single full-length provirus. Cells transfected with provirus expression plasmids expressed similar relative amounts of 3-exon
pX mRNAs but lower levels of 2-exon mRNA forms compared to cells containing a single, full-length provirus. The pX mRNA expression
patterns were nearly identical in cells transfected with wild-type, Tax-minus, or Rex-minus proviruses. Cotransfection of cells with HTLV-1
provirus in combination with SF2/ASF expression plasmid resulted in a relative increase in pX-tax/rex mRNA compared to pX-tax-orfII
and pX-rex-orfI mRNAs, but did not affect exon skipping. Ectopic expression of hnRNP A1 did not affect pX splice site utilization, but
increased exon skipping, as the level of pX-p21rex mRNA was increased by almost 10-fold.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Approximately 20 million people worldwide are infected
with human T cell leukemia virus type 1 (HTLV-1), a
retrovirus that establishes a persistent and lifelong infection.
A subset of infected individuals develop either adult T cell
leukemia (ATL) or a neurodegenerative disease referred to
as tropical spastic paraparesis or HTLV-associated myelop-
athy (TSP/HAM), usually decades after the initial infection
(Bangham, 2000; Johnson et al., 2001; Manns et al., 1999).
Although other cells can be infected with HTLV-1 in vivo
and in vitro, the primary cellular target of the virus is the
T-lymphocyte (Cho et al., 1995; Hanon et al., 2000; Koy-
anagi et al., 1993; Nagai et al., 2001; Richardson et al.,
1990).
The HTLV-1 genome contains a cluster of at least five
open reading frames (ORFs) located near the 3 end that are
highly conserved among HTLV-1 isolates. These pX region
ORFs encode proteins that have known or putative trans-
regulatory functions (Fig. 1A). The Rex and Tax proteins,
encoded by pX ORF X-III and ORF X-IV, respectively, are
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essential for virus expression and replication. Tax interacts
with a variety of cellular proteins to activate transcription of
the virus promoter, to redirect the cellular gene expression
program, and to alter cell-cycle control (Ressler et al., 1996;
Yoshida, 1993, 2001). Rex mediates the nuclear-cytoplas-
mic transport of intron-containing viral mRNAs (Johnson et
al., 2001).
The functions of pX ORFs X-I, X-II, and X-V have been
more difficult to unravel, since the predicted proteins have
not been detected in HTLV-I-infected cell lines and are not
essential for virus replication in vitro (Collins et al., 1999;
Derse et al., 1997). However, in vivo expression of ORF X-I
and ORF X-II is supported by the observation that infected
individuals and experimentally infected animals developed
humoral and cell-mediated immune responses to the respec-
tive peptides (Dekaban et al., 2000; Pique et al., 2000).
Furthermore, HTLV-1 mutants defective for expression of
ORFs X-I and X-II were unable to establish persistent
infections in experimentally infected animals (Bartoe et al.,
2000; Collins et al., 1998). Ectopic expression of recombi-
nant X-I and X-II ORFs have provided some biochemical
clues relevant to their biological functions. Ectopic expres-
sion of the 12-kDa, C-terminal portion of ORF-XI (p12I)
revealed that it accumulated in the endoplasmic reticulum
and Golgi apparatus (Koralnik et al., 1993; Ding et al.,
2001). Biochemical studies showed that p12I was associated
with vacuolar H ATPase (Franchini et al., 1993), MHC I
heavy chain (Johnson et al., 2001), IL-2 receptor  and 
chains (Koralnik et al., 1995, Mulloy et al., 1996), and
calreticulin (Kim et al., 2003). Although the effects of p12I
on T cell activation pathways have been reported (Albrecht
et al., 2000, 2002; Collins et al., 1999; Nicot et al., 2001;
Ding et al., 2002), there is no consensus as to its essential
biological functions. Cells transfected with an ORF X-II
expression plasmid produced a 30-kDa nuclear protein
(p30II) that was reported to inhibit the expression of CREB-
responsive promoters (Zhang et al., 2000, 2001). Expression
of ORF X-V has not been carefully evaluated since the first
HTLV-I isolate to be completely sequenced had a stop
codon in this reading frame (Seiki et al., 1983); however,
ORF X-V is uninterrupted in the majority of HTLV-1 pro-
virus sequences available in the GenBank database.
HTLV-1 structural and regulatory proteins are expressed
from differentially spliced mRNAs (Fig. 1A). The unspliced
mRNA encodes gag, pro, and pol polyproteins. Splicing
from exon 1 in the 5 LTR to an exon 2 splice acceptor site
in the middle of the viral genome generates a singly spliced
mRNA encoding the envelope glycoprotein. Further splic-
ing from exon 2 to splice acceptor sites in the pX region
yields a set of multiply spliced mRNAs. The most abundant
and best studied of these mRNAs is generated using a splice
acceptor site at position 6950 (positions are numbered with
respect to virus mRNA) that encodes Tax and Rex. Alter-
native pX splice acceptor sites at positions 6383, 6478, and
6875 were defined by cloning RT-PCR products derived
from infected cell lines and patient samples (Berneman et
al., 1992; Caputo and Haseltine, 1992; Cereseto et al., 1997;
Ciminale et al., 1992; Koralnik et al., 1992). Translation of
the alternatively spliced pX mRNAs is predicted to follow
the pattern established for Tax and Rex. These proteins are
translated from a bicistronic mRNA using two different
initiation codons in exon 2 such that 20 amino acids from
exon 2 are joined to the Rex ORF or one residue (the other
initiator methionine) is joined to the Tax ORF (Fig. 1B). In
addition to the mRNAs that contain exon 2, cDNA clones
have been isolated in which exon 1 was joined directly to
the pX splice acceptors. The mRNA in which exon 1 is
spliced to the tax/rex acceptor at position 6950 was previ-
ously shown to produce a truncated version of Rex
(p21Rex), which initiates at an internal methionine codon
(Shuh et al., 1999). Likewise, shortened forms of ORFs X-I
and X-II are predicted to originate by translation initiation at
internal AUG codons (Fig. 1B).
The pX proteins, other than Tax and Rex, have not been
detected in HTLV-1-infected cell lines, and the relative
levels of individual, alternatively spliced pX mRNAs have
not been accurately established. Previous methods lacked
the sensitivity and selectivity necessary to resolve a com-
plex mixture of closely related RNAs. We employed real-
time RT-PCR with splice site-specific primers to quantify
the levels of individual pX mRNAs. In chronically infected
T cell lines, pX mRNAs encoding ORFs X-I, X-II, and X-V
were present at levels that were two to four orders of
magnitude lower than the tax/rex mRNA. We also exam-
ined pX mRNA expression profiles in cells transfected with
wild-type and mutant HTLV-1 provirus clones to ask
whether Tax or Rex proteins influenced pX mRNA expres-
sion patterns. Finally, we asked whether overexpression of
the cellular splicing factors SF2/ASF or hnRNP A1 could
modulate alternative splicing of HTLV-1 pre-mRNA.
Results
HTLV-1 RNA splicing
The splicing pattern for HTLV-1 is depicted in Fig. 1A.
Exon 1 is bounded by the mRNA start site at position 1 and
the major splice donor site at position 119. Exon 2 is defined
by alternative splice acceptor sites at positions 4641 and
4658 and by the splice donor site at position 4831. Utiliza-
tion of alternative splice acceptor sites at positions 6383,
6478, 6875, or 6950 in the pX region generates a nested set
of four terminal exons. Alternatively spliced pX mRNAs
can be divided into two groups: mRNAs of the first group
contain exon 1, exon 2, and one of the four terminal pX
exons, while mRNAs in the second group are composed of
exon 1 joined directly to one of the four pX exons. Trans-
lation of the mRNAs that include exon 2 is best understood
for the bicistronic pX-tax/rex mRNA, which uses the pX,
splice acceptor at position 6950 (Fig. 1B). By analogy, the
mRNAs in which exon 2 is spliced to the acceptor sites at
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positions 6383 and 6478 are predicted to yield proteins
containing ORFs X-I, X-II, and X-V. The mRNAs that lack
exon 2 are predicted to initiate translation at internal AUG
codons within the pX ORFs as was previously demonstrated
for the mRNA containing exon 1 joined to the acceptor site
at 6950, yielding pX-p21rex mRNA. Since proteins derived
from ORFs X-I, X-II, and X-V have not been detected in
HTLV-1-infected cells, we focused on quantifying the
steady-state levels of the mRNAs for these proteins. The set
of six pX mRNAs that include or exclude exon 2 and that
use splice acceptors at positions 6383, 6478, and 6950 were
examined. The pX mRNAs are designated by their deduced
translation products or by the exon content and position of
the pX splice acceptor site in the terminal exon; e.g., pX-
Fig. 1. HTLV-1 genetic organization, mRNAs, and known or predicted pX gene products. (A) The 3 end of the HTLV-1 genome encodes five open reading
frames collectively referred to as the pX region. The Rex and Tax proteins are encoded by ORFs X-III and X-IV, respectively, in the distal half of pX.
Products of ORFs X-I, X-II, and X-V, located in the proximal half of pX, have not been detected in HTLV-1-infected cells. The various HTLV-1 mRNAs
are produced by alternative splicing of the genomic mRNA, which encodes gag, pro, and pol genes. The singly spliced mRNA encodes env and multiply
spliced mRNAs encode the various pX proteins, including Tax and Rex. The pX splice acceptor sites examined here are designated by their positions in viral
mRNA and include 6383, 6478, and 6950. Asterisks above exon 2 of the pX mRNAs designate translation start codons for Rex (upstream) and Tax
(downstream). Not shown are the pX mRNAs that exclude exon 2; i.e., that splice from exon 1 directly to one of the pX exons. (B) The known or predicted
translation products derived from pX mRNAs that include exon 2 (left) or exclude exon 2 (right) are shown. The mRNAs are designated according to the
earlier convention based on predicted translation products and by the exons present and the pX splice acceptor site in the terminal exon, in parentheses. In
addition, mRNAs are designated, in parentheses. Translation of the mRNAs that include exon 2 are predicted to start at the Rex (R) or Tax (T) initiation
codons. Translation of the mRNAs that exclude exon 2 are assumed to start at the first in-frame initiation codon (asterisk). Predicted sizes are given in amino
acids (aa).
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tax/rex mRNA is 1/2/6950 (Fig. 1). An additional pX
mRNA was previously identified that used a splice acceptor
at position 6875 and is predicted to encode p13II; however,
we did not examine its expression here.
Real-time RT-PCR conditions
To solve the problem of specifically quantifying an in-
dividual cDNA in a complex mixture of closely related
species, we employed splice site-specific 5 (sense) primers
paired with appropriate 3 (antisense) primers and Taqman
probes (Fig. 2). The 5 portions of the splice site-specific
primers are complementary to approximately 13 bases in the
upstream exon and the 3 portion of the primer is comple-
mentary to four or five bases in the respective downstream
exon. For each alternatively spliced pX mRNA a corre-
sponding cDNA clone was generated and this plasmid DNA
was used to establish optimal real-time PCR reaction con-
ditions, to calibrate cDNA copy number, and to determine
primer specificity.
Real-time PCR reactions were performed with serial
10-fold dilutions of the appropriate cDNA plasmid to give
amounts ranging from 2.5 to 2.5  107 copies per reaction.
Threshold cycle values (Ct) values, defined as the cycle at
which PCR products were detected above the designated
threshold level, were plotted against the log10 of the plasmid
copy number. Calibration plots for all primer pairs used in
this study were linear between 10 and 107 copies of plasmid
DNA targets with correlation coefficients of at least 0.97
and slopes of approximately 3.4.
To determine the specificity of each set of splice site-
specific primers, we compared real-time PCR amplification
kinetics with 106 copies of either cognate or noncognate
cDNA plasmid templates. For each primer pair, the Ct value
obtained with its cognate cDNA plasmid was between 16.4
and 17.7. The Ct values for noncognate plasmids were at
least 10 cycles, and generally 20 cycles higher compared to
cognate cDNAs (data not shown). Primer specificity may be
expressed as the difference between the Ct values for cog-
nate and noncognate cDNAs with a difference between Ct
values of approximately 3 equal to a 10-fold difference in
cDNA copy number. Thus, with respect to cDNA concen-
trations, specificity for a cognate cDNA was three to six
orders of magnitude greater than for an alternative cDNA.
This overall specificity is further demonstrated by the re-
sults obtained with cDNAs from HTLV-1-infected cell lines
shown below.
pX mRNA levels in chronically infected cell lines
The HTLV-1-infected T cell lines chosen for analysis
have been characterized with respect to provirus copy num-
ber and provirus sequence. The MS9 cell line was estab-
lished by infection of primary human T cells with the
molecular clone, pHTLV-X1MT, and contains a single,
full-length provirus (Shuh et al., 1999). MT2 cells contain
Fig. 2. Splice site-specific PCR strategy for real-time PCR amplification of HTLV-1 mRNAs. The pX mRNAs are generated by alternative splicing of either
exon 1 or exon 2 to one of the pX splice acceptor sites at positions 6383, 6478, or 6950. The 5 splice site-specific primers are complementary to 13
nucleotides in exon 1 or exon 2 with four or five nucleotides at the 3 end of the primer complementary to a specific pX exon. The splice junction is designated
in parentheses next to each mRNA and indicated in the primer sequences by (ˆ). PCR amplification specificity is conferred by nucleotide differences at the
3 end of the 5-splice-specific primer, by the location of the 3 primers (3-6552 and 3-7170), and by the Taqman probes (TMP-1 or TMP-2).
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one full-length and at least seven internally deleted HTLV-1
proviruses (Kobayashi et al., 1984). The latter proviruses
have deletions encompassing exon 2 and produce only the
exon 1/pX group of spliced mRNAs. Poly(A) mRNA was
purified from each cell line, converted to cDNA using ran-
dom hexamer primers, and analyzed by real-time PCR with
the splice site-specific primer pairs (Fig. 2).
Copy numbers of alternatively spliced pX mRNAs were
calculated from calibration plots using cDNA plasmids then
normalized to a GAPDH cDNA copy number of 1.0  106 to
compare pX mRNA levels between the cell lines (Table 1).
The total pX mRNA copy number was similar in MS9
and MT2 cells. In MS9 cells the most abundant pX mRNA
was the 3-exon pX-tax/rex (1/2/6950) isoform, which
was present at approximately 15-fold higher levels than the
2-exon pX-p21rex (1/6950) mRNA (Table 1). The rela-
tive amounts of these two mRNAs were inverted in MT2
cells compared to MS9 cells. The higher levels of pX-21rex
(1/6950) mRNA in MT2 cells is attributed to the large
number of internally deleted proviruses in this cell line. The
amounts of pX-tax/rex (1/2/6950) and pX-p21rex (1/
6950) mRNAs in the two cell lines were proportional to the
amounts of p40Tax, p27Rex, and p21Rex proteins that were
previously determined by immunoblotting (Shuh et al.,
1999). The level of pX-rex-orf I (1/2/6383) mRNA was
about 700-fold lower than pX-tax/rex mRNA in both cell
lines. The pX-tax-orf II (1/2/6478) mRNA was present
at 2500-fold lower levels than pX-tax/rex mRNA in MS9
cells and 500-fold lower than pX-tax/rex mRNA in MT2
cells. In MS9 cells, the 2-exon pX-orf I (1/6478) and
pX-orf Ia (1/6383) mRNAs were present at levels 300-
and 1500-fold, respectively, lower than the pX-tax/rex
mRNA. In MT2 cells the relative levels of these 2-exon
mRNAs were 10- to 20-fold higher than in MS9 cells.
pX mRNA splicing in cells transfected with wild-type and
mutant HTLV-1 proviruses
We next examined pX mRNA accumulation in cells
transiently transfected with HTLV-1 provirus expression
plasmids (Table 2). Levels of the 3-exon pX-tax-orf II
(1/2/6478) and pX-rex-orf I (1/2/6383) mRNAs
were 200- and 300-fold lower, respectively, relative to pX-
tax/rex mRNA. These values are comparable to those seen
in the chronically infected cell lines. However, levels of the
2-exon mRNAs, pX-p21rex (1/6950), pX-orf Ia
(1/6383), and pX-orf I (1/6478) were significantly
lower in transfected cells compared to either of the chron-
ically infected cell lines. To test the possibility that viral
trans-regulatory proteins, Tax or Rex, might exert feedback
control of pX mRNA splicing, pX mRNA levels were
compared in cells transfected with either the wild-type
(pCMV-HT1), Tax-minus (pCMVHT-Tax9Q), or Rex-minus
(pCMVHT-Rex1L) versions of HTLV-1 proviruses (Ta-
ble 2). Provirus expression was under the control of the
CMV immediate-early promoter to ensure uniform and
Tax-independent levels of RNA synthesis. There was no
significant difference in the relative distribution of pX
mRNAs in cells transfected with wild-type, Tax-minus, or
Rex-minus proviruses, indicating that Tax and Rex do not
regulate alternative splicing.
Effects of SF2/ASF or hnRNP A1 overexpression on pX
mRNA levels
Alternative splicing may be regulated by the cell type
dependent or condition-specific activities of splicing fac-
tors. Both constitutive and alternative RNA splicing are
Table 1
cDNA cDNA copy number Relative copy number
MS9 MT2 MS9 MT2
pX-tax/rex 1/2/6950 1.93  0.84  106 1.35  0.19  105 1.0  106 1.0  106
pX-tax-orf II 1/2/6478 7.72  4.85  102 2.75  0.58  102 4.0  102 2.0  103
pX-rex-orf I 1/2/6383 2.90  0.40  103 1.84  0.48  102 1.5  103 1.4  103
pX-p21rex 1/6950 1.28  0.16  105 1.87  0.12  106 6.6  104 1.4  107
pX-orfI 1/6478 6.30  2.25  103 9.75  2.85  103 3.3  103 7.2  104
pX-orfIa 1/6383 1.30  0.52  103 7.82  5.52  102 6.7  102 5.8  103
Note. pX mRNA levels in chronically infected cell lines. HTLV-1 pX cDNA copy numbers were determined as described under Materials and Methods
and are normalized relative to 1.0  106 copies of GAPDH cDNA. Mean values from at least three independent experiments are shown with standard
deviations. Relative copy numbers are expressed with respect to 1.0  106 copies of pX-tax/rex cDNA.
Table 2
cDNA Relative copy number
wt TAX REX
pX-tax/rex 1/2/6950 1.0  106 1.0  106 1.0  106
pX-tax-orfII 1/2/6478 5.00  103 5.57  103 3.56  103
pX-rex-orfI 1/2/6383 2.81  103 1.15  103 2.09  103
pX-p21rex 1/6950 3.62  103 3.77  103 4.53  103
pX-orfI 1/6478 74 46 68
pX-orfIa 1/6383 142 41 32
Note. pX mRNA levels in cells transfected with wild-type (wt) and
mutant HTLV-1 provirus expression plasmids. HTLV-1 pX cDNA copy
numbers were determined as described under Materials and methods and
are normalized relative to 1.0  106 copies of pX-tax/rex cDNA. Mean
values from at least three independent experiments are shown. Standard
deviations were within the range shown in Table 1.
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controlled by cis-acting splicing enhancer or suppressor
elements that recruit various cellular accessory proteins
(Ladd and Cooper, 2002). Among these, SF2/ASF and
hnRNP A1 have been shown to positively or negatively
control, respectively, alternative splicing of pre-mRNA
(Caceres et al., 1994; Amendt et al., 1994; Bilodeau et al.,
2001; Blanchette and Chabot, 1999; Chung and Derse,
2001; Damgaard et al., 2002; Fu, 1995; Gontarek and Derse,
1996; Jacquenet et al., 2001; Sun et al., 1993; Tange et al.,
2001; Tange and Kjems, 2001). We asked whether overex-
pression of either SF2/ASF or hnRNP A1 in cells trans-
fected with the HTLV-1 provirus affects HTLV-1 pX
mRNA splicing. To compare the levels of pX mRNAs
among the transfected cell conditions, pX mRNA levels
were expressed relative to pX-tax/rex (1/2/6950)
mRNA (Table 3). In cells transfected with pCMV-HT1,
overexpression of SF2/ASF resulted in a decrease in the
relative levels of pX-tax-orf II (1/2/6478) and pX-rex-
orf I (1/2/6383) mRNAs of 17- and 22-fold, respec-
tively (Table 3). That is, in the group of 3-exon pX mRNAs,
SF2/ASF overexpression promoted the utilization of the
splice acceptor site at position 6950. Overexpression of
SF2/ASF did not significantly alter the relative levels of the
2-exon versus 3-exon mRNAs, indicating that it did not
affect exon 2 recognition.
Unlike SF2/ASF, overexpression of hnRNP A1 did not
significantly affect pX splice acceptor site utilization among
the 3-exon pX mRNAs, since the relative levels of these
mRNAs remained unchanged (Table 3). However, cotrans-
fection with the hnRNP A1 expression plasmid induced a
6.5-fold increase in the level of pX-p21rex (1/6950)
mRNA and a 5-fold increase in the relative level of pX-orf
Ia (1/6383) mRNA. A similar effect was not observed for
pX-orfI (1/6478) mRNA, but the levels of this mRNA
were at the lower limits of detection. Thus, hnRNP A1
overexpression promoted exon 2 exclusion and increased
the levels of the 2-exon pX mRNAs relative to the 3-exon
mRNAs.
Discussion
Real-time RT-PCR with splice site-specific primers pro-
vided the methodology necessary to accurately quantify
each cDNA specific for an individual pX mRNA isoform.
The method has a wide dynamic range and circumvents the
problem of competition or interference among target mole-
cules inherent in other approaches. We first determined the
relative levels of the various pX mRNAs in chronically
infected cell lines and then asked whether viral regulatory
proteins or cellular splicing factors affected their patterns of
expression in transiently transfected cells. The HTLV-1
infected cell lines, MS9 and MT2, were characterized pre-
viously with respect to viral protein expression and provirus
copy number, genetic organization, and nucleotide se-
quence. In cell lines such as MS9, which contain a single
full-length provirus, or in cells transfected with full-length
provirus clones, the pX-tax/rex (1/2/6950) mRNA was
the most abundant of the pX mRNAs. In MS9 cells the
second most abundant pX mRNA was pX-p21rex (1/
6950) mRNA. In MT2 cells, which contain multiple inter-
nally deleted proviruses, the relative amounts of these two
mRNAs were reversed; pX-p21rex mRNA was 15-fold
higher than pX-tax/rex mRNA. Relative levels of pX-tax/
rex and pX-p21rex mRNAs in MS9 and MT2 cells deter-
mined here were proportional to the amounts of p40Tax,
p27Rex, and p21Rex proteins previously determined by
immunoblotting (Shuh et al., 1999).
Besides pX-tax/rex mRNA, two other pX mRNAs in-
clude exon 2 and thus join the tax or rex translation initia-
tion codons to pX ORFs X-I, X-II, or X-V. pX-tax-orf II
(1/2/6478) mRNA is predicted to encode a 30-kDa
Tax-ORF II protein (p30II) and a 21-kDa Rex-ORF V pro-
tein. In ectopic expression experiments, p30II was shown to
be a nuclear protein (Koralnik et al., 1993) which may have
a role in regulating virus gene expression (Zhang et al.,
2000, 2001). The pX-rex-orf V gene product has not been
studied yet because the first HTLV-1 isolate to be se-
quenced had a stop codon interrupting this ORF (Seiki et al.,
1983); this appears to be the exception, since most other
HTLV-1 sequences in the GenBank database predict an
extended open reading frame. The pX-tax-orf II mRNA was
detected at levels that were lower than pX-tax/rex mRNA
by a factor of 2500-fold in MS9 cells, 500-fold in MT2
cells, and 200-fold in provirus-transfected cells. The pX-
rex-orf I (1/2/6383) mRNA encodes a Rex-ORF-I fu-
sion protein of approximately 19 kDa. Ectopic expression of
this cDNA resulted in the detection of a 12-kDa protein,
p12I, which may be generated by translation initiation at an
internal start codon or by posttranslational cleavage of the
larger precursor protein (Ciminale et al., 1992; Koralnik et
al., 1992, 1993). Biochemical analyses of p12I expressed in
transfected cells indicated that it was associated with several
different membrane-associated cellular proteins (Franchini
et al., 1993; Johnson et al., 2001; Koralnik et al., 1995;
Mulloy et al., 1996; Ding et al., 2001; Kim et al., 2003) and
Table 3
cDNA Relative copy number
Vector control SF2/ASF hnRNP A1
pX-tax/rex 1/2/6950 1.00  106 1.00  106 1.00  106
pX-tax-orfII 1/2/6478 5.00  103 0.29  103 3.06  103
pX-rex-orfI 1/2/6383 2.81  103 0.13  103 2.62  103
pX-p21rex 1/6950 3.62  103 2.89  103 23.5  103
pX-orfI 1/6478 74 29 49
pX-orfIa 1/6383 142 480 717
Note. pX mRNA levels in cells transfected with HTLV-1 provirus
expression plasmid in combination with empty vector (vector control),
SF2/ASF, or hnRNP A1 expression plasmids. HTLV-1 pX cDNA copy
numbers were determined as described under Materials and methods and
are normalized relative to 1.0  106 copies of pX-tax/rex cDNA. Mean
values from at least three independent experiments are shown. Standard
deviations were within the range shown in Table 1.
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affects T cell signal transduction pathways (Albrecht et al.,
2000, 2002; Nicot et al., 2001; Ding, 2002). The pX-rex-orf
I mRNA was detected at levels that were 700-fold lower
than pX-tax/rex mRNA in MT2 and MS9 cells and 360-fold
lower in cells transfected with HTLV-1 provirus. The pX-
orf I (1/6478) and pX-orf Ia (1/6383) mRNAs do not
include exon 2 and therefore would initiate translation at a
start codon within ORF X-I to produce p12I. In MS9 cells
pX-orf I and pX-orf Ia mRNAs were expressed at about
300- and 1500-fold lower levels, respectively, compared to
pX-tax/rex mRNA. In MT2 cells, these mRNAs, similar to
the pX-p21rex mRNA, accumulated at higher levels than in
MS9 cells. In contrast, pX-orf I and pX-orf Ia mRNAs were
barely detectable in cells transfected with HTLV-1 provirus.
Assuming that relative mRNA levels are proportional to the
levels of their encoded proteins, it is not surprising that the
ORF X-I and ORF X-II gene products have not been de-
tected in HTLV-1-infected cell lines.
The two previous attempts to estimate the levels of
alternatively spliced pX mRNAs in cells transfected with a
cloned HTLV-1 provirus or in HTLV-1-infected cell lines
gave results quite different than those determined here. In
the former case, Northern blotting was used to show that
pX-rex-orf I and pX-tax-orf II mRNAs together were ex-
pressed at about 20-fold lower levels than the singly spliced
env mRNA (Ciminale et al., 1992). Since this method could
not distinguish between the two pX mRNAs and because of
its narrow dynamic range, Northern blotting provided only
an approximate estimation of relative mRNA levels. In
another study, RNase protection assays with probes that
spanned alternative mRNA splice sites were employed to
examine pX mRNA levels in various HTLV-1-infected cell
lines (Cereseto et al., 1997). While this method has much
greater sensitivity than Northern blotting, there are still
inherent problems with specificity and quantification when
applied to complex mixtures of closely related mRNAs.
These problems are exemplified by results which showed
that pX-tax-orf II mRNA was expressed at two- to seven-
fold higher levels than the pX-tax/rex mRNA in two HTLV-
1-transformed cell lines (Cereseto et al., 1997). These val-
ues are not consistent with our quantitative real-time PCR
data nor with previous Northern blotting results (Ciminale
et al., 1992).
There is strong immunological data indicating that the
proteins encoded by ORF X-I and ORF X-II mRNAs, p12I
and p30II, are expressed in infected individuals and in ex-
perimentally infected animals (Dekaban et al., 2000; Pique
and Dokhelar, 2000; Pique et al., 2000). Furthermore, ex-
perimental infections with cloned proviruses indicated that
p12I and p30II were necessary for virus propagation and
persistence in vivo (Bartoe et al., 2000; Collins et al., 1998).
In contrast, these proteins have not been detected, and their
mRNAs are expressed at very low levels, in chronically
infected cell lines; in addition, ORF X-I and X-II genes are
dispensable for HTLV-1 infection or transformation of T
cells in vitro (Collins et al., 1999; Derse et al., 1997). The
expression of pX ORFs of HTLV-1 is reminiscent of the
papillomavirus oncogenes. Papillomaviruses are small
DNA tumor viruses that establish persistent infections of
epithelial cells and induce epithelial hyperplasias that occa-
sionally progress to malignant neoplasms (Stubenrauch and
Laimins, 1999). In addition to a transcriptional activator
(E2), bovine papilloma virus (BPV-1) encodes three regu-
latory proteins (E5, E6, and E7) that alter the cellular en-
vironment and have oncogenic activity. Expression of these
three proteins is dependent on cell differentiation and re-
pressed by viral regulatory proteins E1 and E2 (Vande Pol
and Howley, 1995). The BPV-1 E5 protein was observed in
fibropapillomas; E7 was expressed at low levels, but E6 was
not detected (Bohl et al., 2001). Analogous to the expression
of p12I and p30II in HTLV-1-transformed T cell lines,
neither E5 nor E7 proteins were detected in transformed
C127 cells, even though the proteins were biologically ac-
tive (Bohl et al., 2001). An important question that remains
to be answered is whether p12I and p30II proteins and their
mRNAs are expressed at higher levels in vivo compared to
cell lines grown in vitro. It is possible that the proteins are
naturally expressed at low levels but in sufficient amounts to
accomplish their biological functions. Alternatively, the
HTLV-1-transformed cell lines may present a snapshot of a
particular aspect of the HTLV-1 gene expression program.
In vivo, levels of pX mRNAs may be modulated by cellular
factors in response to specific environmental stimuli and
could be expressed at higher levels at specific points in the
virus life cycle.
In the absence of an in vitro model system that recapit-
ulates the in vivo HTLV-1 life cycle, we asked whether viral
regulatory proteins or cellular splicing factors could modu-
late pX mRNA levels in transfection experiments. We were
unable to detect significant shifts in specific pX mRNA
levels in cells transfected with Tax-minus or Rex-minus
proviruses, arguing against a role for Tax or Rex as repres-
sors of pX mRNA expression. Overexpression of the splic-
ing factors SF2/ASF and hnRNP A1 have been shown to
modulate alternative RNA splicing in other retrovirus sys-
tems (Amendt et al., 1994; Bilodeau et al., 2001; Blanchette
and Chabot, 1999; Chung and Derse, 2001; Damgaard et al.,
2002; Gontarek and Derse, 1996; Jacquenet et al., 2001; Sun
et al., 1993; Tange et al., 2001; Tange and Kjems, 2001).
SF2/ASF belongs to the SR family of proteins involved in
both constitutive and alternative splicing and whose activity
is dependent on cell type, differentiation, or activation status
(Fu, 1995). When cotransfected with HTLV-1 provirus,
SF2/ASF caused a decrease in pX-tax-orf II and pX-rex-orf
I mRNA levels relative to pX-tax/rex mRNA, suggesting
that pX mRNA expression could be modulated in a condi-
tion-specific manner. The protein hnRNP A1 was previ-
ously shown to oppose the effects of SF2/ASF (Caceres et
al., 1994). Although it did not affect the utilization of the
alternative pX splice acceptor sites when overexpressed in
transfected cells, it did cause exon 2 skipping, resulting in
increased levels of pX-p21rex and pX-orfI mRNAs. These
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cotransfection experiments provided a limited test of cellu-
lar factors that could potentially affect pX mRNA alterna-
tive splicing; further analyses of the viral cis-acting ele-
ments and the cellular trans-acting factors that interact to
modulate pX mRNA and protein expression are in progress.
Materials and methods
Cells and transfections
The human T cell line HUT78 and HTLV-1-infected
human T cells, MS9, MT2, and C8166, were grown in
RPMI 1640 medium supplemented with 10% fetal calf
serum and antibiotics. MS9 cell-culture medium also con-
tained 100 U/ml of IL-2. Transformed human kidney 293T
cells were maintained in DMEM with 10% fetal calf serum
and antibiotics. Human 293T cells (3  106 cells in 10-cm
plates) were transfected with 10 g of plasmid DNA by
calcium phosphate coprecipitation as previously described
(Shuh et al., 1999).
Plasmids
The plasmid pCMV-HT1 contains the full-length
HTLV-1 provirus in which the 5 LTR was replaced by a
CMV promoter containing a 5 splice site (Shuh et al.,
1999). pCMVHT-Tax9Q was derived from pCMV-HT1 by
site-directed mutagenesis, which changed a CAG (Gln)
codon in Tax to TAG (stop); this C-to-T change at position
6970 did not affect the overlapping Rex amino acid se-
quence. pCMVHT-Rex1L was also constructed by site-
directed mutagenesis of pCMV-HT1 to change the Rex
initiation codon from ATG (Met) to CTG (Leu). The A-to-C
change is at nucleotide position 4772 of viral genomic
mRNA. Mutations were confirmed by nucleotide sequenc-
ing and phenotypes were verified in functional assays. A
portion of each alternatively spliced HTLV-1 mRNA, en-
compassing the characteristic splice junction, was ampli-
fied by RT-PCR from chronically infected cell lines and
cloned into the pCRII-TOPO vector (Invitrogen). The
cloned cDNAs were verified by nucleotide sequencing
and were used to establish calibration curves in real-time
PCR reactions or to define primer specificity. The fol-
lowing cDNA clones are listed by name with the virus
sequence positions and exon definitions in parentheses;
splice sites are indicated by slash marks. pB5-5 (78–119/
4658–4831/6950–7278; 1/2/6950); pMS9-2.1 (4819–
4831/6383– 6551; 2/6383); pMS9-11.1 (4819 – 4831/
6478 – 6551; 2/6478); pMS9-7.8 (78 –119/6950 –7278;
1/6950); pMT2-2.3 (105–119/6383– 6552; 1/6383);
pMT2-5.4 (105–119/6478 – 6552; 1/6478); pMT2-2.8
(105–119/4658–4921; 1/env4658); pMS9-8 (105–119/
4641–4921; 1/env4641).
RNA purification and cDNA synthesis
HTLV-I-infected cell lines, MS9, MT2, C8166, and
transfected 293T cells, were harvested and washed with
phosphate-buffered saline. Total RNA was extracted from
the cells using the RNeasy kit (Qiagen) and poly(A)RNA
was then prepared using the Oligotex kit (Qiagen). All
quantitations were done by 260-nm absorbance measure-
ments. cDNAs were then prepared by reverse transcription
of 0.5 to 1.0 g of poly(A) mRNA using Omniscript RT
(Qiagen) as described by the manufacturer’s protocol.
Real-time PCR
Real-time PCR and analysis of cDNA amplification
products were performed on a Prism 7700 sequence detector
(Perkin Elmer/Applied Biosystems, Foster City, CA), using
96-well optical plates and strip caps from the same supplier.
The reaction conditions were 50°C for 2 min, 95°C for 10
min to activate the DNA polymerase, and then 50 cycles of
15 s at 94°C and 1 min at 60°C. All reaction volumes were
25 l, including 5 l of cDNA template, 20 l of a PCR
master mix (Applied Biosystems), 100 ng of each primer,
and water. Calibration curves were derived by running 10-
fold dilutions of the various cDNA plasmids diluted in TLE
(20 mM Tris–HCl, pH 7.5; 0.1 mM EDTA) over the range
of 2.5  100 to 2.5  107 copies. The cDNA samples were
run at several dilutions. Each assay included duplicate wells
for each dilution of calibration plasmids, triplicate wells for
each sample cDNA, and controls which included nonspe-
cific plasmid DNA, buffer, or water, all in duplicate. The
threshold cycle values were used to plot the calibration
curve. Standard curve data were graphed using Microsoft
EXCEL 2000, which derived the equation for the line and
calculated the coefficient of variation (CV). All standard
curves had a CV of at least 0.97. The copy number of a
particular cDNA in a sample was calculated from its mea-
sured Ct value with respect to the calibration plot. The copy
numbers were normalized to the human GAPDH values
measured in separate real-time PCR assays with the
GAPDH kit (Perkin Elmer/Applied Biosystems) and
GAPDH DNA standards from Intergen, Inc. All copy num-
bers derived are the result of at least six determinations.
Real-time PCR reactions were performed using SYBR
green or Taqman detection methods with nearly identical
results.
PCR primers
The 5 splice site-specific PCR primer sequences are sum-
marized in Fig. 2. Other primers included: ex1/44641env, 5-
TCCGCCGTCTAGCTTC-3; ex1/4658env, 5-TCCGCCG-
TCTAGCCGC-3; 3-6552, 5-GGAGAAAGCAGGAAGA-
GC-3; 3-7170, 5-GAGTCGAGGGATAAGGAAC-3;
3-4921, 5-CTGTAATCACCGAAGATGAG-3; 3-6552,
5-GGAGAAAGCAGGAAGAGC-3; and 3-7170, 5-GA-
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GTCGAGGGATAAGGAAC-3. For real-time PCR reactions
in which a Taqman approach was used, the probe for 1/
6383, 1/6478, 1/2/6383, or 1/2/6478 cDNAs
was TMP-1 (P12/30TQM): 5 FAM-TTCGCCT-
TCTCAGCCCCTTGTCT-TAMRA-3. The Taqman
probe for 1/6950 and 1/2/6950 cDNAs was TMP-2
(HT039-TQM): 5-FAM-ATCACCTGGGACCCCATC-
TAMRA-3.
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